“I’m particularly skeptical about the use of SNPs to determine whether someone is going to develop a disease or respond or not respond to a drug. The cost of generating SNPs is going to be very low, but the cost of generating phenotypes is going to be very high, and that’s rate limiting.”
David Martin, president and CEO of EOS Biotechnology, speaking at the BIO CEO and Investors Conference in New York City in February